The distributions of eGFR, heart failure (Stage C), history of diabetes, myocardial infarction, atrial fibrillation, presence of proteinuria, and the use of heart failure medications, such as β-blockers and SGLT2 inhibitors, were similar across the dosage groups. This evidence concerns the gene SLC5A2 and atrial fibrillation.